Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Am J Respir Crit Care Med · 2019 · PMC6857485 · PMID 31729908

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally statistically significantno p-value reported

Summary of the evidence Previous studies showed an increase of the likelihood of treatment success when cycloserine was included in the MDR-TB regimen (marginally statistically significant) ( 96 ).

also in 1,110 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.